Skip to main content
ATOSSA THERAPEUTICS, INC. logo

ATOSSA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ATOS ISIN · US04962H5063 US Manufacturing
Open in API
Filings indexed 622 across all filing types
Latest filing 2016-08-26 Capital/Financing Update
Country US United States of America
Listing US ATOS

About ATOSSA THERAPEUTICS, INC.

https://atossatherapeutics.com/

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative medicines for areas of significant unmet medical need, with a primary focus on oncology. The company is dedicated to addressing the full continuum of breast cancer care. Its lead program is centered on (Z)-endoxifen, a proprietary and potent selective estrogen receptor modulator (SERM). Atossa is advancing (Z)-endoxifen through clinical development for multiple breast cancer indications, including metastatic disease, aiming to provide a therapeutic with a potentially improved efficacy and tolerability profile.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically discusses a reverse stock split (a capital structure change) effective August 26, 2016, including amendments to the certificate of incorporation. It also references exhibits such as the certificate of amendment and a press release. The document is short (2732 characters) and serves as an announcement of a corporate action rather than a detailed financial report or earnings release. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as stock splits.
2016-08-26 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the U.S. SEC, which is a current report used to announce major events that shareholders should know about. The content describes a termination agreement and settlement of litigation, a cash payment received, and compliance with Nasdaq listing requirements. It does not contain financial statements or detailed financial analysis, nor is it a full annual or quarterly report. It is not a proxy, earnings release, or management discussion. The document is a regulatory announcement of a material event, typical of an 8-K filing, which fits best under Regulatory Filings (RNS) as a general category for miscellaneous SEC filings that do not fit other specific categories. The document length is under 5,000 characters and is a standalone announcement, not a report itself.
2016-08-23 English
FORM 10-Q
Interim / Quarterly Report Q2 2016
2016-08-12 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 12, 2016, reporting the issuance of a press release announcing second quarter 2016 financial results and a company update. The text explicitly states that the press release is attached as Exhibit 99.1 and incorporated by reference. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of such information. The length of the document is 3132 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the 'MENU VS MEAL' rule, this is an announcement of a report (press release of financial results) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and includes Form 8-K filings announcing events or press releases.
2016-08-12 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the termination of a material definitive agreement and settlement of litigation between Atossa Genetics Inc. and Besins Healthcare Luxembourg SARL. It includes details about the termination agreement, settlement payment, and dismissal of legal action. There are no financial statements or comprehensive financial data presented, nor is this an annual or quarterly report. The document is not a proxy, earnings release, or management discussion. It is a regulatory announcement of a significant corporate event, specifically the termination of a material agreement and settlement of litigation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2016-08-05 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated July 27, 2016. It primarily announces the attachment of a corporate presentation provided to investors on the same date, which is incorporated by reference. The document does not contain detailed financial statements or substantive financial data but rather serves as a notice of the presentation's availability. The length is under 5,000 characters, and the text states the presentation was previously posted on the company's website. This fits the criteria for a Regulatory Filing (RNS) as it is a general regulatory announcement and does not constitute a full report or detailed financial disclosure.
2016-07-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.